AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Provider of intelligence-driven marketing and sales automation services intended to help growing businesses make meaningful connections with their customers. The company's customer experience automation platform (CXA) offers marketing automation, email marketing, transactional email, sales automation, and customer relationship management (CRM), providing clients with a personalized, automation-first approach that allows teams to save time and effectively connect with customers.
Developer of reviews collection and management solutions designed to collect genuine texts and video reviews from happy customers. The company's platform helps increase advertisement click-through rate, lowers its cost-per-click, provides past customer reviews to build trust in the company, displays product review solutions for growing brands, manages online reputation across third-party platforms, and more, thereby helping brands build trust through review collection.
SparkLayer is the powerful platform that transforms your existing website into a fully featured B2B solution. Rapid to setup, simple to use, and integrates beautifully with your existing systems.
AstraZeneca is a global pharmaceutical company focused on the research, development, and commercialization of prescription medicines. With around 90,000 employees in 85 countries, the company aims to harness scientific advancements for the benefit of people and society. AstraZeneca operates in various functions, including Clinical Development, Regulatory Affairs, Finance, IT, and Manufacturing.
The company specializes in three main therapeutic areas: oncology, respiratory, and immunology. In oncology, AstraZeneca is dedicated to developing innovative treatments that aim to redefine cancer care. In the respiratory and immunology sectors, the company works to improve outcomes for patients with asthma and COPD, as well as other immune-driven diseases. Additionally, AstraZeneca has expanded its focus on rare diseases through its acquisition of Alexion, enhancing its capabilities in this area. The company is committed to advancing science and creating impactful therapies across multiple health conditions.